- Home
- Equipment
- united kingdom
- cancer systemic therapy
Refine by
Cancer Systemic Therapy Equipment Supplied In United Kingdom
30 equipment items found
by:Edinburgh Molecular Imaging based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and ...
by:Edinburgh Molecular Imaging based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Recombinant human monoclonal antibody expressed in CHO binding to human ANGPT2. Anti-ANGPT2 Therapeutic Antibody is a monoclonal antibody designed for the treatment of ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
Both inside and out, the human body harbours ecosystems of micro-organisms, including bacteria, viruses, fungi and archaea. These microorganisms, their genomic potential and their collective repertoire of activity are known as ‘the ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs and other bioconjugates are emerging as one of the ...
Manufactured by:Oxford Vacmedix UK Limited based inOxford, UNITED KINGDOM
Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they will attack the tumour and provide an effective treatment against it. Injecting a preparation that stimulates these T Cells effectively vaccinates the ...
Manufactured by:Yourgene Health based inManchester, UNITED KINGDOM
Elucigene DPYD assay is a simple genotyping test that can identify patients with DPD deficiency allowing an alternative treatment to be offered. 5-fluorouracil (5-FU) is a chemotherapy agent used to treat a range of cancers including colorectal, head and neck, breast, pancreatic and stomach cancer. 5-FU is metabolized by the dihydropyrimidine dehydrogenase enzyme (DPD) which is encoded by the ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Two transgenes: Producing a secreted CD40 agonist monoclonal antibody. Currently in clinical trials in the US and UK. ...
Manufactured by:Sequana Medical NV based inSint-Denijs Westrem, BELGIUM
Ascites is also a common complication of certain late-stage cancers due to fluid build-up in the peritoneal cavity from a number of causes including draining of the lymph system. While life expectancy for many cancer patients with malignant ascites is short (less than 3 months), ovarian and breast cancer patients often have longer life expectancies. In 2018, the incidence in the U.S. and EU5 is ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial ...
Manufactured by:Exscientia based inOxford, UNITED KINGDOM
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
Manufactured by:Camurus AB based inLund, SWEDEN
episil® oral liquid is a medical device for treatment of inflammatory and painful conditions in the oral cavity. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces, as well as severe inflammation caused by e.g. oral mucositis, a common and serious side effect of cancer treatment. In contact with the buccal membrane, episil® transforms into a thin ...
Manufactured by:Exscientia based inOxford, UNITED KINGDOM
In the landmark study, it was demonstrated for the first time that our functional precision-oncology platform can improve patient outcome in a prospective interventional ...
Manufactured by:Immunodiagnostic Systems Holdings PLC based inBoldon Colliery, UNITED KINGDOM
LISA-TRACKER anti-Trastuzumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of anti-Trastuzumab antibodies in human serum ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB006 is an allogeneic CAR-T product targeting B7-H4 for the treatment of cancers arising from solid tumors. B7-H4 antigen is overexpressed in breast cancers, especially triple negative breast cancer, and ovarian cancers, both diseases with acute clinical needs. There are 270,000 new cases of breast cancer and 23,000 new cases of ovarian cancer per year in the US. It is also implicated ...
by:Oncimmune Holdings PLC based inNottingham, UNITED KINGDOM
Oncimmune’s proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers that can help stratify patients in multiple cancer indications and with different autoimmune ...